Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief
Commercial Officer and Michael Nally Named Chief Marketing Officer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Adam H. Schechter, president of
Global Human Health (GHH), is stepping down from his current position as of Dec. 31, 2018, and will be shifting to an advisory
capacity to the CEO. The company is taking the opportunity to reshape its commercial organization and is creating two new Executive
Committee roles. Frank Clyburn has been promoted to Chief Commercial Officer and Michael Nally has been promoted to Chief Marketing
Officer.
Schechter has been the president of GHH since 2010. He joined the company in 1988. Schechter has been responsible for the
performance of our human health business during a period of significant change, and also evolved Merck’s commercial organization to
strengthen the company’s ability to bring its medicines and vaccines to people in more than 140 countries around the world. In
addition to his accomplishments in Merck’s commercial organization throughout his 30-year career, Schechter led the integration of
Merck and Schering-Plough, a significant milestone in the creation of today’s Merck.
“Adam’s leadership and unwavering dedication to finding new ways to bring Merck’s medicines and vaccines to more patients around
the world have been hallmarks of his time at Merck. I have relied on his experience and expertise as we evolved a world-class
commercial organization, spanning primary care, hospital and specialty, vaccines and oncology,” said Kenneth C. Frazier, Chairman
and Chief Executive Officer, Merck. “Because of him we are better positioned to address future opportunities and challenges as a
global biopharmaceutical company, and Frank and Mike have a great foundation upon which to build future success.”
“It has been my honor to be a part of Merck for 30 years and to lead Global Human Health since 2010,” Schechter said. “I am
proud of how we have transformed our business and have been able to ensure that Merck’s remarkable medicines and vaccines are
available to so many people around the world. I know that Frank and Mike share that passion for achieving Merck’s mission, and I am
confident that they will build on GHH’s track record of driving growth and continue the momentum we have across our global business
today.”
Frank Clyburn, who will take on the role of Chief Commercial Officer, effective Jan. 1, 2019, has held a number of leadership
positions across Merck. Most recently, Clyburn was the President of the Global Oncology business. In his new role, Clyburn will
report directly to Ken Frazier and will be a member of the Executive Committee. He will be responsible for all operations and
P&L across Merck’s human health commercial portfolio globally. Clyburn joined Merck in 2008 and has had responsibility for
numerous global pharmaceutical franchises, including diabetes, cardiovascular and women’s health, as well as leadership of
marketing and sales teams.
Michael Nally, who will become Chief Marketing Officer, effective Jan. 1, 2019, most recently led the company’s Vaccines
business. In his new role, Nally will report directly to Ken Frazier and will be a member of the Executive Committee. Nally will be
responsible for Global Marketing and long-term franchise strategy across the portfolio. Nally has been at Merck since 2003 and
served in a number of roles with responsibilities including being the Managing Director of UK, Ireland and Sweden as well a variety
of roles in Commercial Operations, Business Development and Investor Relations.
About Merck
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada,
has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our
prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than
140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect
with us on
Twitter,
Facebook,
Instagram,
YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends toward health care cost containment; technological advances,
new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results to differ materially from those described in the
forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Media Contacts:
Pam Eisele, (267) 305-3558
Jennifer Mauer, (908) 740-1808
Investor Contacts:
Peter Dannenbaum, (908) 740-1037
Teri Loxam, (908) 740-1986
View source version on businesswire.com: https://www.businesswire.com/news/home/20181210005816/en/